Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decreased tetranectin in multiple myeloma.

H Nielsen1, I Clemmensen, H J Nielsen

  • 1Department of Hematology, Hvidovre University Hospital, Copenhagen, Denmark.

American Journal of Hematology
|February 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing.

BMC cancer·2018
Same author

Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration.

The International journal of biological markers·2017
Same author

A randomized pilot study on single-port versus conventional laparoscopic rectal surgery: effects on postoperative pain and the stress response to surgery.

Techniques in coloproctology·2014
Same author

Mannan-binding lectin (MBL)-associated serine protease-1 (MASP-1), a serine protease associated with humoral pattern-recognition molecules: normal and acute-phase levels in serum and stoichiometry of lectin pathway components.

Clinical and experimental immunology·2012
Same author

The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.

International journal of obesity (2005)·2011
Same author

Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer.

Scandinavian journal of immunology·2011

Serum tetranectin levels are significantly reduced in multiple myeloma patients, regardless of treatment status. These low tetranectin levels may indicate cancer progression or a chronic disease state.

Area of Science:

  • Biochemistry
  • Oncology
  • Human Physiology

Background:

  • Tetranectin is a human protein involved in cell growth and differentiation.
  • Previous studies noted decreased tetranectin in solid malignant tumors.
  • Tetranectin's role in cancer pathophysiology requires further investigation.

Purpose of the Study:

  • To investigate serum tetranectin levels in multiple myeloma patients.
  • To determine the correlation between tetranectin levels and clinical parameters.

Main Methods:

  • Serum samples were collected from multiple myeloma patients (untreated and treated).
  • Serum tetranectin levels were quantified.
  • Statistical analysis was performed to assess correlations.

Related Experiment Videos

Main Results:

  • Serum tetranectin levels were significantly reduced in multiple myeloma patients compared to controls.
  • No significant correlation was found between tetranectin levels and serum albumin, hemoglobin, or M-component.
  • Minimal interindividual variation in tetranectin levels was observed.

Conclusions:

  • Reduced serum tetranectin is a characteristic finding in multiple myeloma.
  • Low tetranectin may be associated with tumor growth, metastasis, or a general catabolic state in chronic disease.